Mylan to Pay $57 Million to Settle Drug Overpricing Claims

Bloomberg

Mylan Inc. (MYL), the generic-drug company, agreed to pay $57 million to settle claims it caused the U.S. and California to overpay for drugs.

The settlement, filed yesterday in federal court in Boston, came in cases filed by Ven-A-Care of the Florida Keys Inc., a specialty pharmacy. California will get $26.3 million, the U.S. will get $22.2 million, and Ven-A-Care and its attorneys will get $8.5 million, court records show.